AGTR1 and Alzheimer disease: Thus, it is possible that during aging, AD-relevant risk factors and stressors (e.g., APOE4, Aβ) disrupt normal homeostatic functions of AT1 receptor signaling in glia, which underlies the mechanisms of how ARB treatment improves behavior.